| Nilotinib studied in …STUDIED_INderived134 of 134show fewer |
|---|
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 134 trials list this drug (16 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03516279Phase 2 · active not recruiting Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04971226Phase 3 · active not recruiting A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05456191Phase 3 · active not recruiting A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04838041Phase 2 · recruiting Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03906292Phase 2 · active not recruiting Frontline Asciminib Combination in Chronic Phase CML · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01698905Phase 2 · completed Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554341Phase 2 · active not recruiting Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial · 134 trials list this drug (16 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02029001Phase 2 · recruiting Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment · 134 trials list this drug (16 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00756509Phase 4 · completed Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03874858Phase 2 · terminated A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04877522Phase 4 · recruiting Asciminib Roll-over Study · 134 trials list this drug (16 active) | — | — | Leukemia,Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05185947Phase 2 · completed Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis · 134 trials list this drug (16 active) | — | — | Appendix Neoplasm,Malignant Breast Neoplasm,Peritoneal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01774630Phase 2 · completed Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03784014Phase 3 · completed Molecular Profiling of Advanced Soft-tissue Sarcomas · 134 trials list this drug (16 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03578367Phase 2 · completed Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. · 134 trials list this drug (16 active) | — | — | Leukemia,Myeloid Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07493408Phase 2 · not yet recruiting Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01207492Phase 2 · completed Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor · 134 trials list this drug (16 active) | — | — | Tenosynovial Giant Cell Tumor,Tenosynovial Giant Cell Tumor, Diffuse Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04903119Phase 1 · recruiting Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma · 134 trials list this drug (16 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01407198Phase 1 · completed Nilotinib With Radiation for High Risk Chordoma · 134 trials list this drug (16 active) | — | — | Chordoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03654768Phase 2 · active not recruiting Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01316250NA · completed Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02917720Phase 2 · active not recruiting 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07138378Phase 1 · completed A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions. · 134 trials list this drug (16 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06409936Phase 2 · recruiting PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205903Phase 1 · completed Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01751425Phase 1 · terminated Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01804985Phase 2 · completed De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04147533Phase 2 · active not recruiting Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01863745Phase 2 · completed Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02326311Phase 3 · completed Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02081378Phase 1 · completed A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01735955Phase 4 · completed Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study · 134 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia,Gastrointestinal Stromal Tumor,Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 134 trials list this drug (16 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05286528completed Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04681820unknown Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01806571Phase 2 · completed Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01657604Phase 3 · completed TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04518644no longer available Nilotinib, for Patients With CML-CP or CML-AP · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02269267Phase 2 · completed The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study) · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03885830completed Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01025505Phase 2 · completed Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04559555no longer available MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 134 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02546674Phase 4 · completed Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01884922Phase 1 · completed Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02353728Phase 2 · completed Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04835584Phase 1/Phase 2 · unknown KRT-232 and TKI Study in Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03942094Phase 3 · unknown Nilotinib for First-line Newly Diagnosed CML-CP Patients · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02602314Phase 4 · unknown Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00481052Phase 2 · completed Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00769327Phase 2 · completed Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02627677Phase 3 · terminated A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00644878Phase 2 · terminated Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01743989Phase 3 · completed A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00980018Phase 4 · completed An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00109707Phase 1/Phase 2 · completed A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia,Systemic Mastocytosis,B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01131325Phase 4 · terminated Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive,Poroid Hidradenoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01844765Phase 2 · completed Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02973711Phase 1/Phase 2 · withdrawn A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01856283Phase 2 · completed Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01702064Phase 1 · completed Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01077544Phase 1 · completed A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) · 134 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01223898Phase 1 · completed To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00384228Phase 1/Phase 2 · completed A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia,B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01279473Phase 1/Phase 2 · completed Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) · 134 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia,Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00471497Phase 3 · completed A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01914484Phase 1/Phase 2 · completed Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive,Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive,Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04578847Phase 2 · unknown A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01274351Phase 2 · completed Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01528085Phase 2 · completed Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01140568Phase 2 · completed Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas · 134 trials list this drug (16 active) | — | — | Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01155817Phase 1 · completed Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease · 134 trials list this drug (16 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01744665Phase 2 · completed A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02225574Phase 1 · terminated An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00036738Phase 2 · completed Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib · 134 trials list this drug (16 active) | — | — | Adult Acute Lymphoblastic Leukemia,Childhood Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00976612completed Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02115386Phase 3 · terminated Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02174445Phase 3 · terminated An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02611492Phase 3 · unknown A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00129740Phase 2 · completed Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02272777Phase 3 · completed A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02253277Phase 1 · completed Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03079505Phase 3 · terminated Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00788775Phase 2 · completed Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma · 134 trials list this drug (16 active) | — | — | Melanoma,Acral Melanoma,Mucosal Lentiginous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02709083Phase 2 · terminated Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Leukemia,Myeloid Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01866553Phase 2 · terminated Nilotinib Plus Pegylated Interferon-α2b in CML · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01535391Phase 3 · completed Nilotinib in PH+, BCR-, ABL+ CML Patients · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00809211Phase 2 · completed Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03332511Phase 4 · completed Efficacy and Safety of Nilotinib in CML-CP · 134 trials list this drug (16 active) | — | — | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02108951Phase 3 · terminated Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors. · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03228303early Phase 1 · unknown Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02774512early Phase 1 · withdrawn Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer · 134 trials list this drug (16 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00702403Phase 1/Phase 2 · completed Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML · 134 trials list this drug (16 active) | — | — | Adult Acute Lymphoblastic Leukemia,Childhood Acute Lymphoblastic Leukemia,Childhood Chronic Myeloid Leukemia, BCR-ABL1 Positive+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01395121Phase 2 · completed A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread · 134 trials list this drug (16 active) | — | — | Mucosal Lentiginous Melanoma,Acral Lentiginous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01605981Phase 4 · withdrawn Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01275586early Phase 1 · completed Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas · 134 trials list this drug (16 active) | — | — | Neurofibroma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01089595Phase 2 · terminated Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02086487Phase 4 · terminated Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00264160Phase 2/Phase 3 · completed Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy · 134 trials list this drug (16 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01110668Phase 2 · completed Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01126892Phase 3 · completed A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01206088Phase 4 · completed Tasigna in Glivec-resistant or Intolerant Patients in CML · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01061177Phase 4 · completed Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00718562Phase 2 · completed Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00786812Phase 4 · completed Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01289028Phase 3 · completed Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01368523Phase 4 · completed Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00760877Phase 3 · completed Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00785785Phase 3 · completed A Study of Nilotinib Versus Imatinib in GIST Patients · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00750659Phase 2 · completed Nilotinib Pre and Post Allogeneic Stem Cell Transplantation · 134 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02733445completed Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01043874Phase 4 · completed Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01275196Phase 3 · completed Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01254188Phase 3 · completed Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01227577Phase 4 · completed CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01028222Phase 2 · completed A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation · 134 trials list this drug (16 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01099514Phase 2 · completed Study of Nilotinib in Metastatic Melanoma With KIT Aberrations · 134 trials list this drug (16 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00802841Phase 3 · completed Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01670084Phase 2 · withdrawn Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia · 134 trials list this drug (16 active) | — | — | Adult Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive,Adult B Acute Lymphoblastic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00905398Phase 1/Phase 2 · terminated Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 134 trials list this drug (16 active) | — | — | Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01222143Phase 1/Phase 2 · terminated Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02389920Phase 4 · unknown Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00751036Phase 3 · terminated Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01562847unknown Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00782834Phase 2 · terminated Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01261429Phase 2 · completed Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) · 134 trials list this drug (16 active) | — | — | Tenosynovial Giant Cell Tumor, Diffuse Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00762632Phase 1/Phase 2 · completed Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01270893Phase 2 · withdrawn Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST) · 134 trials list this drug (16 active) | — | — | Malignant Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00905593approved for marketing Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00471328Phase 3 · completed Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib · 134 trials list this drug (16 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00519090Phase 3 · terminated Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00302016no longer available Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia · 134 trials list this drug (16 active) | — | — | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00413270no longer available Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant · 134 trials list this drug (16 active) | — | — | Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01168050Phase 2 · unknown Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. · 134 trials list this drug (16 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |